Trial Profile
A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Acronyms HARBOUR; KEYNOTE-348
- Sponsors Amgen
- 07 Jun 2022 Status changed from active, no longer recruiting to discontinued, according to results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results (data cut off date- June 10, 2021), presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 29 Jan 2021 Planned End Date changed from 26 Mar 2026 to 31 Jan 2025.